ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / TLSI / forecast
BDSX (40) XGN (36) YDES (44) BNR (20) ⌘ Pro Terminal →

TriSalus Life Sciences Inc. (TLSI) 12-Month Stock Forecast & Price Target Cone

$3.63 -1.89% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.61

TriSalus Life Sciences Inc. (TLSI) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $227.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TLSI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TLSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, TriSalus Life Sciences Inc. (NASDAQ: TLSI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $3.63 (-1.89% 1D, market cap $227.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TLSI ranks #799 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TLSI compare to BDSX and XGN in the Health Care sector?
▼

Within the Health Care sector (Medical Specialities), TLSI carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 84.6%, and ROIC of -35.0%. By comparison, BDSX (Biodesix Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $245.4M) and XGN (Exagen Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $208.1M). Among the 5-stock peer group, TLSI leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TLSI?
▼

Per TLSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001826667), TriSalus Life Sciences Inc. generated $45.2M in revenue (+53.4% YoY), -$39.2M in net income, and -$18.9M in free cash flow against $35.3M in total assets and $33.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.61 (-0.53%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (9)Whales (3)SEC (11)Macro (4)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.7% Base Target
$8 Bull$3 Base$2 Bear
📬 FREE TLSI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TLSI)Realized 20D OHLCV Swing Band: ±11.6%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY TLSI SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (37% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (30% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 84.6% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$4.00-8.5% Next Q
Q2 (-2Q)
35
Grade E$3.66+3.8% Next Q
Q3 (-1Q)
33
Grade E$3.80-4.5% Next Q
Current
30
Grade E$3.63-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TLSI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TLSI currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.38) and Max Pain ($3.81) forces dealer call-delta covering toward $8.35.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TLSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TLSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your TLSI Position Size: $10,000

Shares at $3.63: 2754.8 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $2.47
$6,804
$-3,196 (-32.0%)
12M Consensus BaseTarget $3.17
$8,733
$-1,267 (-12.7%)
12M Bull Case BreakoutTarget $8.35
$23,003
+$13,003 (+130.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$374%A
Goldman SachsSector Coverage LeadUNDERPERFORM$869%B
JP MorganUS Large-Cap ResearchSELL$358%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TLSI)

  • ✓Walkthrough of TLSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TLSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.43%🛡️ HOLDING TREND SUPPORT
2026-11-03O $3.86H $3.86L $3.63C $3.63VOL 108.6K
RES: $5.75SUP: $3.50SMA50: $4.38SMA200: $4.38
$6.17$5.09$4.02$2.94$1.87RES $5.75SUP $3.50$3.632026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TLSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TLSI Butterfly Map → + Track TLSI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +53.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TLSI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TLSI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TLSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TLSI)

Health Care Rank #799 of 1016 ⚔️ BDSX vs TLSI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TLSI vs. BDSX, XGN, YDES, BNR)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, TriSalus Life Sciences Inc. (TLSI) ranks #799 by composite RQD confidence (30/100, grade E) and #554 by equity capitalization ($227.8M). Within this direct 5-issuer industry benchmark cohort, TLSI leads on earnings valuation at N/A trailing P/E, while YDES leads on capital efficiency and profitability with -20.0% ROIC and 28.1% gross margin. YDES currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with TLSI at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TLSI ACTIVE
TriSalus Life Sciences Inc.
E 30/100 — 84.6% -35.0% -1.89% $227.8M Benchmark Subject
BDSX
Biodesix Inc.
D- 40/100 — — -35.0% -6.34% $245.4M /bdsx-vs-tlsi →
XGN
Exagen Inc.
D- 36/100 — 58.3% -35.0% -2.33% $208.1M /xgn-vs-tlsi →
YDES
YD Bio Limited
D 44/100 — 28.1% -20.0% +0.51% $420.7M /ydes-vs-tlsi →
BNR
Burning Rock Biotech Limited
E 20/100 — 74.7% -35.0% -7.89% $115.0M /bnr-vs-tlsi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001826667

In its most recent audited fiscal period (FY2025, filed 2025-12-31), TriSalus Life Sciences Inc. (TLSI) reported GAAP revenue of $45.2M (+53.4% vs. FY2024 revenue of $29.4M , and +143.9% cumulative change since FY2023) , GAAP net income of -$39.2M, operating cash flow of -$18.0M, and free cash flow of -$18.9M (+54.0% YoY). On the balance sheet, TLSI closed FY2025 with $35.3M in total assets against $33.0M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $45.2M -$39.2M -$18.0M -$18.9M $35.3M $33.0M
FY2024 (FY) 2024-12-31 $29.4M -$30.0M -$40.8M -$41.2M $24.0M $22.1M
FY2023 (FY) 2023-12-31 $18.5M -$59.4M -$50.6M -$50.6M — —

3. TLSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TLSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, TriSalus Life Sciences Inc. (NASDAQ: TLSI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $3.63 (-1.89% 1D, market cap $227.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TLSI ranks #799 in composite RQD confidence.

How does TLSI compare to BDSX and XGN in the Health Care sector?

Within the Health Care sector (Medical Specialities), TLSI carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 84.6%, and ROIC of -35.0%. By comparison, BDSX (Biodesix Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $245.4M) and XGN (Exagen Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $208.1M). Among the 5-stock peer group, TLSI leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TLSI?

Per TLSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001826667), TriSalus Life Sciences Inc. generated $45.2M in revenue (+53.4% YoY), -$39.2M in net income, and -$18.9M in free cash flow against $35.3M in total assets and $33.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TLSI trading relative to its 50-day, 200-day, and 52-week technical levels?

TLSI last traded at $3.63 (-1.89% on volume of 230,913 shares), positioning the stock -17.12% below its 50-day simple moving average ($4.38) and -17.12% below its 200-day simple moving average ($4.38). Across its 52-week range of $2.20 to $7.95, TLSI sits at the 24.9% percentile with a 14-day RSI of 40.4 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($3.21 to $4.05).

Direct Sub-Reports: TLSI RQD Cockpit TLSI 12M Forecast TLSI Earnings & Move TLSI Dividends & DRIP TLSI Insiders & 13F TLSI Whale Options TLSI Profit Sankey TLSI News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

TLSI — TriSalus Life Sciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

TriSalus Life Sciences Inc. (TLSI) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.63 (-1.89% 1D, market capitalization $227.8M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 84.6%, operating margin of -59.7%, and free cash flow yield of -7.96%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (4/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

TriSalus Life Sciences Inc. Is listed on NASDAQ under ticker TLSI and is classified in the Health Care sector, Medical Specialities industry. Revenue reported for FY 2025 is $45.2M, . The business profile in the source data is limited to sector and market classification.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), TriSalus Life Sciences Inc. (TLSI) reported $45.2M in annual revenue (up from $29.4M in FY2024, +53.4% YoY) and -$39.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($18.5M revenue, -$59.4M net income) through FY2025, TLSI scaled operating cash flow to -$18.0M and free cash flow to -$18.9M, backed by $35.3M in total assets against $33.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.96% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.20 – $7.95 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -59.7% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The only sector context available is the Health Care / Medical Specialities classification. An investor should treat this section as an absence of mapped ripple effects rather than evidence that none exist.

  • Key Question #1: Can TLSI sustain or expand its -59.7% operating margin and -35.0% ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $45.2M and free cash flow of -$18.9M, how will capital allocation balance growth reinvestment against $33.0M in total debt?
  • Key Question #3: How sensitive is TLSI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TLSI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for TriSalus Life Sciences Inc. (TLSI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TLSI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TLSI Bull vs. Bear Conversation Board — What's Your Call at $3.63?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TLSI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TLSI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $4.44 (+20.0%)
📌 Pinned Debate

Revenue grew from $18.5M to $45.2M over FY 2023 to FY 2025 while operating losses narrowed from -$54.5M to -$26.9M.

Long TLSI at $3.70 targeting $4.44. Revenue grew from $18.5M to $45.2M over FY 2023 to FY 2025 while operating losses narrowed from -$54.5M to -$26.9M.. Institutional whale score is 3/20 and the risk/reward vs. the $2.20 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

Both sides have a point here — TLSI's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $2.85 (-23.0%)
Spot @ $3.70

ROIC of -35% and FCF of -$18.9M in FY 2025 show the business is still consuming cash with an RQD score of 31 and E grade.

Fading this rally in TLSI at $3.70. ROIC of -35% and FCF of -$18.9M in FY 2025 show the business is still consuming cash with an RQD score of 31 and E grade.. With a beta of 1.0 and the stock sitting at $3.70 (52-wk range $2.20–$7.95), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%